NCT02532777|UnknownPhase 2
Loading search results
Sponsor study identifier
interventional
100
1 country
1
Study Start
August 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN in children.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2015
Date type not reportedThis date has not been verified as actual or estimated.
August 20, 2015
Actual (reported)August 26, 2015
Actual (reported)July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Disappearance of proteinuria
The proteinuria is \< 150mg/d
30 mo
Disappearance of hematuria
30 mo
Renal function
30 mo
Drug: prednisone \& cyclophosphamide \& Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod. cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.
Drug: prednisone \& mycophenolate mofetil \& Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod. mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.
Nanjing Children's Hospital
Nanjing, Jiangsu, 210000, China
Hahn D, Hodson EM, Craig JC. Interventions for preventing and treating kidney disease in IgA vasculitis. Cochrane Database Syst Rev. 2023 Feb 28;2(2):CD005128. doi: 10.1002/14651858.CD005128.pub4.
Aihua Zhang, M.D.
Department of Nephrology, Nanjing children's hospital
First Submitted
August 20, 2015
First Posted
August 26, 2015
Study Start
August 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2020
Study of Treatment Response on IgG4 Related Disease (IgG4RD)
Drug: prednisone \& leflunomide \& Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod. Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
February 26, 2020
Record last verified: 2020-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: